Nexium I.V. (Esomeprazole)

Esomeprazole, the active ingredient in Nexium I.V., is a proton pump inhibitor presented as an injectable solution for intravenous use. It reduces gastric acid secretion and is employed to treat gastro‑esophageal reflux disease, prevent stress‑related ulcer bleeding, and manage erosive esophagitis in acute care settings.

GNH USA supplies Nexium I.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory conformity for intravenous gastro‑protective therapy through reliable cold‑chain logistics where required.

Esomeprazole, a proton pump inhibitor, reduces gastric acid production and is used in several acid‑related gastrointestinal conditions.

- Gastro‑esophageal reflux disease (GERD): provides rapid acid suppression to relieve symptoms and promote healing of the esophageal mucosa. - Stress ulcer prophylaxis: prevents bleeding in critically ill or postoperative patients by maintaining a low gastric acidity. - Erosive esophagitis: facilitates healing of ulcerated esophageal tissue through sustained reduction of acid exposure.

Esomeprazole administered intravenously may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild headache reported. - Diarrhea: loose stools. - Nausea: transient nausea. - Injection site reactions: erythema or mild pain.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis. - Hypomagnesemia: low magnesium with prolonged use. - Anaphylaxis: life‑threatening allergic reaction.

When using Nexium I.V., clinicians should observe several precautionary measures to ensure patient safety and product integrity. - Assess renal function: adjust use in patients with severe renal impairment. - Monitor electrolytes: check magnesium and potassium levels during prolonged therapy. - Evaluate for drug interactions: avoid concurrent use with drugs that require gastric acidity for absorption. - Use cautiously in patients with hepatic impairment: dose may need adjustment. - Discontinue if signs of infection appear: watch for C. difficile-associated diarrhea. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Esomeprazole may affect the pharmacokinetics of several co‑administered medicines, requiring attention to interaction potential.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption and efficacy. - Dasatinib: lowered plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR. - Digoxin: increased serum levels. - Methotrexate: reduced renal clearance. - HIV protease inhibitors (e.g., ritonavir): altered metabolism.